- Details
- In a comprehensive discussion led by Charles Ryan, James Gulley delves into the role of genomic testing and immunotherapy in treating prostate cancer. Dr. Gulley emphasizes the importance of personalized treatment, highlighting studies that identify specific genomic markers like homologous recombination deficiency and mismatch repair deficiency. These markers can guide the use of targeted therapie...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the recently published article in the Lancet Oncology, "Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: A prospective, registry-based, single-arm, observational, evaluation study." Patients with oligometastatic disease have a more favorable prognosis than those with widespread metastati...
|
- Details
- The United States Food and Drug Administration (FDA) approved Orgovyx (relugolix), the first and only oral GnRH receptor antagonist for the treatment of patients with advanced prostate cancer. Alicia Morgans, MD, MPH, and Charles Ryan, MD discuss Orgovyx and what it means to men being treated for advanced prostate cancer who now have an oral ADT treatment option. The FDA approval of Orgovyx is bas...
|
- Details
- Speaking with Alicia Morgans, Karim Fizazi discusses the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer. Enzalutamide has previously been shown to postpone the time to metastasis or death. Data presented at ASCO 2020 demonstrated that overall survival is significantly improved in patients receiving enzalutamide — median overall survival w...
|
- Details
- Fred Saad joins Alicia Morgans to discuss the updated data from the PROSPER trial of enzalutamide for nonmetastatic castration-resistant prostate cancer. The updated results show that enzalutamide not only improves metastasis-free-survival, as was indicated by the results published in 2018 but also significantly extends overall survival. Biographies: Fred Saad, MD, FRCS, Professor and Chief of Uro...
|
- Details
- Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels. Neal Shore joins Alicia Morgans to discuss the results of the HERO phase 3 trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. Relugolix is an oral, once a day medication, and the trial had a primary endpoint of non...
|
- Details
- Stephen Freedland joins Alicia Morgans to discuss the Carbohydrate and Prostate Study 2 (CAPS2), a randomized controlled trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer. This study is part of a series of studies looking at the role of low carbohydrate diets in prostate cancer. The study involved taking men with rising PSA after failed s...
|
- Details
- Matthew Sydes joins Alicia Morgans to share his perspective on the data supporting a patient’s decision whether to use docetaxel or whether to use AR pathway inhibitors at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). The two discuss the direct and indirect methods of trial comparison and examine the data from trials that reported on docetaxel as well as the abiraterone clinical...
|
- Details
- Ana Aparicio joins Alicia Morgans at ASCO GU 2020 to discuss her work with AR indifferent tumors in the field of prostate cancer. Among the topics discussed, Dr. Aparicio stressed the importance of understanding clinical features and the development of a profile of this AR indifferent subtype in order to allow for easier identification. The two further discuss the research and ongoing clinical tri...
|
- Details
- Charles Ryan sits down with Rahul Aggarwal to discuss one of the first of its kind, the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic providing comprehensive care to men with prostate cancer who are receiving androgen deprivation therapy (ADT). While ADT is extremely effective, it causes side effects, including fatigue, hot flashes, and sexual changes, such as decreased libido (se...
|
